1-855-378-42281-855-378-4228
One of the outpatient treatment options for clients in Hadar battling with opioid dependence and addiction is called opioid maintenance therapy. Some centers and doctors are certified to administer specific medications to opioid addicted individuals, many of which are opioid-based themselves and are addictive. With low doses the user doesn't experience high feelings and also doesn't experience intense cravings and is not in opioid withdrawal. Methadone is the first medication administered for this reason, but there are a few more choices to choose from.
Methadone is an opiate and can be taken at an outpatient medical center licensed to dispense the drug, that is taken on a daily basis as a pill or liquid. The cost of the med is approximately $150 a month. Buprenorphine is also an opioid-based med, and is in pill form often taken every other day. But different from Methadone which is only be given in highly structured medical centers, Buprenorphine can be prescribed and administered in doctor's offices. The monthly cost of buprenorphine is approximately three hundred dollars /month for the generic version of the med. There is also a version of buprenorphine that contains the ingredient naloxone, which is a drug which reverses the effects of opioids. An individual taking this version of the drug, AKA Suboxone, would find it harder to get high from opioids if they relapsed while taking the drug. It too is taken on a daily basis, and is priced approximately $450 /month. Naltrexone is an additional drug taken in opioid maintenance therapy, but unlike the other medications mentioned here it is an opiate blocker and isn't an opiate. A person has the choice to take this medication as a monthly injection, which is called Vivitrol. As an opioid blocker, it prevents a person from experience being high from opioids, and in turn lowers the risk associated with relapse. This daily injection costs anywhere from $1000 to $1200 per month.
For All Alcohol and Drug Treatment Centers In Hadar, Click Here.
